dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
Published 7 years ago • 368 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:48
dr. pinilla-ibarz on the role of chemotherapy in cll
-
1:14
dr. pinilla-ibarz on the impact of venetoclax in cll
-
1:12
javier pinilla-ibarz, md, phd: treatment options for patients with previously treated cll
-
0:52
dr. pinilla-ibarz discusses advancements in cml
-
1:29
dr. james on update of ibrutinib for chronic lymphocytic leukemia
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
9:03
up-front ibrutinib versus fcr for patients with cll
-
2:42
dr. rogers discusses early intervention with ibrutinib in cll
-
0:51
dr. seymour on role of ibrutinib in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:00
dr. smith on ibrutinib-based therapies in cll
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
1:24
how ibrutinib has transformed the treatment paradigm of cll
-
4:59
comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk cll
-
2:14
dr. jeffrey jones on idelalisib and ibrutinib in patients with cll
-
6:13
jeff p. sharman, md: ublituximab plus ibrutinib improves response rate in high-risk cll
-
7:17
the use of ibrutinib in cll
-
0:54
dr. davids discusses ongoing research with ibrutinib plus venetoclax in cll
-
0:41
dr. chavez on combination of ibrutinib plus ublituximab in cll